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While gastric bypass surgery remains popular as the only treatment for morbid obesity with curative potential,
the molecular mechanisms underpinning its immediate metabolic benefits remain unclear. New work in this
issue (Troy et al., 2008) suggests intestinal glucose production sensed by afferent nerve fibers surrounding
the portal vein may be key.Got a sweet tooth? If so, it’s not usually
considered a good thing—at least for
your metabolic health. But has anyone
heard of a sweet duodenum? A few flights
further down your digestive tract, right
past your stomach, may be a sugar-gen-
erating spot that could actually help
keep circulating blood glucose levels low
and hunger pangs in check. In this issue,
Andreelli and colleagues (Troy et al.,
2008) present experimental evidence
that endogenous glucose production by
defined segments of the small intestine
regulates food intake and hepatic glucose
metabolism via the autonomic nervous
system, and may also play a key role in
the immediate and substantial metabolic
benefits conferred by some bariatric sur-
geries.
Despite a mortality risk of 0.5%–2%
(depending on where it is performed),
bariatric gastric bypass surgery is an in-
creasingly popular treatment option for
obese patients. An estimated 120,000
procedures were performed in the US
alone in 2002—twice the number oper-
ated 5 years earlier (Couzin, 2008). The
typical clinical bypass procedure, Roux-
en-Y gastric bypass (RYGB), couples
substantial gastric reduction with an in-
testinal rerouting that excludes the duo-
denum and proximal jejunum from direct
contact with nutrients. Substantial weight
loss is the result, at least partly accounted
for by a precipitous drop in food intake fol-
lowing surgery. Unexpectedly, gastric by-
pass surgery also has almost immediate
metabolic benefits that precede any sub-
stantial weight loss, observations that
were initially overlooked by the scientific
community (Pories et al., 1987; Pories
et al., 1995). Bariatric surgery is estimated
to offer the potential to reduce diabetes
deaths by more than 90% (Adams et al.,
2007), igniting serious discussion as towhether surgery could be the most effi-
cient treatment for diabetes—even in pa-
tients without a great excess of body adi-
posity. In light of this potential expansion
of the indications for bariatric surgery, un-
derstanding the physiological and molec-
ular mechanisms underlying its benefits
becomes imperative.
In their new paper, Mithiuex, Andreelli,
and colleagues compare energy and glu-
cose metabolism following two experi-
mental bariatric surgical procedures with
sham operations, in high-fat diet-induced
obese (HF-DIO) mice (Figure 1). In the first
procedure, they used a restrictive pros-
thetic band around the upper stomach
to create a small proximal and a large dis-
tal pouch, connected by a narrow lumen
(gastric lap band, GLB). Alternatively,
they performed an enterogastric anasto-
mosis with pyloric sphincter ligature that
excluded duodenum and proximal jeju-
num from contact with ingested nutrients
(entero-gastro anastomosis [EGA]), per-
formed as a surrogate for the clinical
RYGB. EGA mice had significantly de-
creased food intake, and when sham-
control and GLB mice were pair-fed to
the EGA mice, body fat loss was similar
in all groups, suggesting that at least in
the paradigm used here, changes in
weight were a consequence of caloric
intake and not differences in energy
expenditure.
More importantly, the authors observed
in EGA mice significant improvements in
the ability to clear a glucose load as early
as 10 days after surgery. This was due in
part to increased insulin secretion, but
EGA animals also showed a clear im-
provement in the sensitivity of hepatic
glucose production to suppression by
insulin. This enhanced insulin response
might be explained by increased secre-
tion of the gastrointestinal hormoneCell Metabolism 8,GLP-1, previously implicated as one me-
diator of bariatric surgery’s immediate
metabolic benefits. In EGA mice however,
GLP-1 action did not seem to be respon-
sible for improved hepatic insulin sensitiv-
ity. The authors also did not see changes
in hepatic lipid content in EGA treated
mice. Instead, they present compelling
tracer dilution and arteriovenous sam-
pling evidence indicating that intestinal
gluconeogenesis was directly linked to the
improved hepatic glucose metabolism in
the EGA mice. In prior studies, the authors
have proposed that intestinal gluconeo-
genesis may regulate afferent nerve fibers
that connect with the food intake circuitry
of the central nervous system circuitry
(Mithieux et al., 2005). In the current
work, the EGA procedure increased intes-
tinal glucose production sufficiently to
raise portal vein glucose levels as com-
pared to sham-operated controls. This re-
sponse appeared to be key to improving
glucose tolerance and insulin sensitivity.
In further studies, mice that lack portal
vein glucose sensing (due to tissue-spe-
cific deficiency for the glucose transporter
GLUT2) did not exhibit decreased food
intake and improved glucose metabolism
following EGA compared to surgically
treated wild-type controls. Consistent
with the notion that portal vein glucose
sensing signals are relayed to the CNS by
visceral nerves, local destruction of sen-
sory fibers in the vicinity of the portal
vein attenuated EGA-induced metabolic
improvements, including the effects on
food intake.
These results suggest that intestinal ad-
aptations may underlie the beneficial ef-
fects of gastric bypass. Rapid passage
of meals into the gut of EGA animals, in
the absence of normal gastric, pyloric,
and duodenal function to regulate nutrient
delivery, increases GLP-1 but also causesSeptember 3, 2008 ª2008 Elsevier Inc. 177
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a state of higher glucose pro-
duction. That this latter effect
changes the response of
local neural networks projec-
ting to the CNS suggests that
EGA initiates several actions
that could mediate metabolic
benefit, as has been pro-
posed previously (Berthoud,
2008; Vincent and le Roux,
2007).
What is the relevance of
these interesting findings to
clinical bariatric surgeries?
The bypass technique used
here in mice by Troy and col-
leagues differs from RYGB in
that the stomach is fully ex-
posed to incoming nutrients
in the EGA, rather than the
substantial gastric reduction
performed in human patients.
The exclusion of the duode-
num and proximal jejunum
from direct contact with
nutrients may be a key com-
ponent of the near instant im-
provement of diabetic condi-
tions following RYGB (Rubino
et al., 2006). Consistent
with this model, EGA mice
showed distinct improve-
ments in glucose tolerance
compared to GLB animals
despite similar amounts of
food intake (which differed
little even without pair feed-
ing), body weight, and body
fat. Unclear, however, is
how these findings will translate into hu-
man (patho-)physiology, for which differ-
ing effects of banding versus bypass on
body weight are well documented.
Other questions are raised by the stim-
ulating data of by Troy and colleagues.
While the study of the EGA procedure
was thorough, analysis of the GLB model
was limited due to (in some cases fatal)
gastric obstruction and regurgitation. Al-
though the expression of key gluconeo-
genic enzymes were not increased in GLB
mice (as contrasted with EGA mice),
tracer dilution and arteriovenous sam-
pling data would have been useful to con-
firm that intestinal glucose production did
not increase. And while most of the data
in this paper is internally consistent, the
model proposed by the authors would
be strengthened by a demonstration that
preventing intestinal gluconeogenesis
prevents the effects of EGA. Also of
interest is whether the GLUT2 knockout
or deafferentation experiments would
worsen glucose tolerance in the GLB or
sham controls. These shortcomings pre-
vent definitive conclusions on the EGA
model. Moreover, gastric restriction ap-
pears to be much less well tolerated in
mice than men, so the rodent work should
not dissuade continued clinical use of the
much less invasive and less risky AGB
procedure.
Recently described cases of dramatic
hypoglycemia in RYGB patients (Service
et al., 2005) raise some doubt as to
whether the immediate metabolic bene-
fits of bariatric surgery are always desir-
able. After all, the metabolic
derangements associated
with obesity tend to appear
slowly over time. Clearly
chronic negative energy bal-
ance over time, with concom-
itant loss of excess fat, will
lead to resolution of the meta-
bolic syndrome. Since, in
most patients, gastric bypass
surgery causes just this sort
of gradual weight loss, are
those unexplained immediate
benefits of RYGB truly
needed? Some of the long-
term liabilities of RYGB, such
as reoccurring hypoglycemia
are plausibly, even likely,
a consequence of the same
changes in gut neural and en-
docrine function that appear
so miraculous in the immedi-
ate postoperative period.
Tellingly, no one has yet re-
ported serious and undesired
side effects from curing type
2 diabetes the old fashioned
way—by decreasing food in-
take and increasing exercise.
Nevertheless, the work
presented here by Troy and
colleagues adds a new layer
of complexity and constitutes
a novel approach to dissect-
ing the mechanisms behind
surgically induced metabolic
improvement. While it seems
unlikely, at least for now,
that gastric surgery will be-
come a primary treatment
option for diabetes in lean individuals,
the role of intestinal glucose production
for bariatric success warrants future stud-
ies and may pave the way for new strate-
gies to prevent or treat the metabolic syn-
drome. Would devices providing specific
delivery of small amounts of glucose di-
rectly into the portal vein be effective for
diabetes? Or would implanted pace-
makers specifically stimulating afferent
nerve bundles surrounding the portal
vein decrease appetite? Will a well-timed
shot of GLP-1 give both approaches an
additional boost? Clear answers to these
questions would undoubtedly put re-
searchers and surgeons in a sweet spot
to solve one of today’s most discussed
biomedical mysteries—but, more impor-
tantly, may open up the opportunity to
Figure 1. Schematic View of the Mechanistic Model Proposed by
Troy et al.
Glucose produced by defined intestinal segments is secreted directly into the
portal vein, where changes in blood glucose are detected by sensory fibers
presumably projecting to central nervous system circuits controlling food
intake, insulin secretion, and nutrient partitioning. Enhanced intestinal glucose
production following bariatric surgeries that bypass duodenum and jejunum
may explain some of the immediate metabolic benefits that occur after such
surgeries, but not following gastric banding procedures. ANS, autonomic ner-
vous system; EGA, entero-gastro anastomosis.178 Cell Metabolism 8, September 3, 2008 ª2008 Elsevier Inc.
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too.
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transcription factors, and expression of
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creased gluconeogenic gene expression
(Zhang et al., 2006). Notably, mice hetero-
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nases, in addition to Akt, can phosphory-
late FOXO. However, FOXO is one of
many transcription factors contributing
to PEPCK expression; therefore, full re-
pression in the presence of insulin may re-
quire activation of an as-yet-unidentified
signaling complex by p110b and may
occur in a PIP3-independent manner (see
Figure 1A). Alternatively, p110b catalytic
activity and PIP3 production might be re-
quired for repression of PEPCK by insulin.
It is known that pharmacologic inhibition
of p110b does not block acute Akt phos-
phorylation, but it does significantly inhibit
PIP3 generation. This observation raises
the possibility that while p110a activation
alone produces more than sufficient PIP3
for acute AKT activation, additional PIP3-
dependent responses that require higher
levels of this lipid or that require PIP3 pro-
duction at a unique location by p110b play
additional roles in suppression of gluco-
neogenesis.
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